In Pfizer Business Review, Established Products Unit Is Most "Complex," Simmons Says
This article was originally published in PharmAsia News
Executive Summary
With Pfizer Inc. in the midst of a strategic business review that includes an evaluation of all business units outside the "innovative core," even the company's Established Products business unit - made up of mature pharmaceuticals that have lost exclusivity in developed markets - could be spun out or put up for sale